Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817677 | 0.83 | ENPP2 (0.40) | MAOAENPP2GRM5GRM1 | |
| SCHEMBL1816546 | 0.81 | ENPP2 (0.38) | ENPP2 | |
| SCHEMBL6873994 | 0.81 | PIK3CG (0.38) | ENPP2BMPR1AACVRL1ACVR1 | |
| SCHEMBL12003882 | 0.80 | MAP3K11 (0.42) | MAOA | |
| SCHEMBL1819577 | 0.80 | GRM2 (0.39) | MAOAGRM5GRM1 | |
| SCHEMBL1815307 | 0.80 | ENPP2 (0.43) | ENPP2GRM5GRM1 | |
| SCHEMBL1816940 | 0.78 | FSHR (0.38) | ENPP2 | |
| SCHEMBL1814754 | 0.77 | ENPP2 (0.42) | MAOAENPP2GRM5GRM1GABRA1 | |
| SCHEMBL1818195 | 0.77 | CYP2C9 (0.38) | MAOAENPP2GRM5GRM1 | |
| SCHEMBL1817540 | 0.76 | GRM5 (0.39) | MAOAENPP2GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIN3A, GRIN2D | MAOA 133/4885ENPP2 2659/4885GRM5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.